Clinical trials / NCT06005974
NCT06005974Phase 2Terminated

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

Study sponsor: Recursion Pharmaceuticals Inc. · RXRX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2025-02-24Actual
Enrollment · participants18Actual
Source updated2026-02-23Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: To evaluate the safety and tolerability of REC-4881 Measure: To evaluate the preliminary anti-tumor activity of REC-4881 as measured by Objective Response Rate (ORR)

+ After

Measure: Number of Participants with Dose Limiting Toxicities Measure: Objective Response Rate

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

60 participants (planned)

+ After

18 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

Jan 2027

+ After

24 Feb 2025

Recruitment status changed

− Before

Active not recruiting

+ After

Terminated

Check registry source